These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 12703164

  • 1. [Current treatment of tuberculosis].
    García Ramos R, Lado Lado FL, Túnez Bastida V, Pérez del Molino Bernal ML, Cabarcos Ortiz de Barrón A.
    An Med Interna; 2003 Feb; 20(2):91-100. PubMed ID: 12703164
    [Abstract] [Full Text] [Related]

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 3. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES, Mallampalli A.
    Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
    [Abstract] [Full Text] [Related]

  • 4. Treatment of tuberculosis in children.
    Cruz AT, Starke JR.
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):939-57. PubMed ID: 19053906
    [Abstract] [Full Text] [Related]

  • 5. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases.
    Shin S, Guerra D, Rich M, Seung KJ, Mukherjee J, Joseph K, Hurtado R, Alcantara F, Bayona J, Bonilla C, Farmer P, Furin J.
    Clin Infect Dis; 2003 Apr 15; 36(8):996-1003. PubMed ID: 12684912
    [Abstract] [Full Text] [Related]

  • 6. Approaches to improving adherence to antituberculosis therapy--South Carolina and New York, 1986-1991.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 1993 Feb 05; 42(4):74-5, 81. PubMed ID: 8429808
    [Abstract] [Full Text] [Related]

  • 7. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents.
    Drobac PC, del Castillo H, Sweetland A, Anca G, Joseph JK, Furin J, Shin S.
    Clin Infect Dis; 2005 Jun 01; 40(11):1689-92. PubMed ID: 15889370
    [Abstract] [Full Text] [Related]

  • 8. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005.
    Pozniak AL, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, Collins S, Lucas SB, BHIVA Guidelines Writing Committee.
    HIV Med; 2005 Jul 01; 6 Suppl 2():62-83. PubMed ID: 16011537
    [No Abstract] [Full Text] [Related]

  • 9. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M, Shirakawa T.
    Kekkaku; 2005 Sep 01; 80(9):613-29. PubMed ID: 16245793
    [Abstract] [Full Text] [Related]

  • 10. [Tuberculosis--current therapeutic concepts].
    Grünhage F, Sauerbruch T, Spengler U.
    Dtsch Med Wochenschr; 2005 Jan 28; 130(4):159-64. PubMed ID: 15662583
    [No Abstract] [Full Text] [Related]

  • 11. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
    Cox HS, Niemann S, Ismailov G, Doshetov D, Orozco JD, Blok L, Rüsch-Gerdes S, Kebede Y.
    Clin Infect Dis; 2007 Jun 01; 44(11):1421-7. PubMed ID: 17479936
    [Abstract] [Full Text] [Related]

  • 12. [Reform of Japan's NTP and its technical perspectives].
    Mori T.
    Kekkaku; 2004 Oct 01; 79(10):587-604. PubMed ID: 15631111
    [Abstract] [Full Text] [Related]

  • 13. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2006 Mar 24; 55(11):301-5. PubMed ID: 16557213
    [Abstract] [Full Text] [Related]

  • 14. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaeili M, Farnia P, Tabarsi P, Amiri MV, Mirsaeidi M, Mansouri D, Masjedi MR, Velayati AA.
    Int J Infect Dis; 2009 Sep 24; 13(5):e236-40. PubMed ID: 19285897
    [Abstract] [Full Text] [Related]

  • 15. Are second-line drugs necessary to control multidrug-resistant tuberculosis?
    Nardell EA, Mitnick CD.
    J Infect Dis; 2006 Nov 01; 194(9):1194-6. PubMed ID: 17041843
    [No Abstract] [Full Text] [Related]

  • 16. Beyond DOtS: avenues ahead in the management of tuberculosis.
    Chaudhury RR, Thatte U.
    Natl Med J India; 2003 Nov 01; 16(6):321-7. PubMed ID: 14765625
    [Abstract] [Full Text] [Related]

  • 17. Treatment of extensively drug-resistant tuberculosis and role of the pharmacist.
    Mitrzyk BM.
    Pharmacotherapy; 2008 Oct 01; 28(10):1243-54. PubMed ID: 18823220
    [Abstract] [Full Text] [Related]

  • 18. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL, Xie YG, Tan WG, Chu NH, Li L, You YH, Yang YZ, Wang XM, Yan XL, Miao ZP, Duanmu HJ.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb 01; 30(2):179-83. PubMed ID: 19565883
    [Abstract] [Full Text] [Related]

  • 19. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct 01; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 20. Current concepts in the management and prevention of tuberculosis in adults.
    Fox CW, George RB.
    J La State Med Soc; 1992 Aug 01; 144(8):363-8. PubMed ID: 1453094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.